28 Jan 2016
Clariant welcomes Britta Fuenfstueck as new member of the Executive Committee
Muttenz, January 28, 2016 – Clariant, a world leader in specialty chemicals, announced today the appointment of Britta Fuenfstueck as a new member of its Executive Committee. Britta Fuenfstueck, former CEO of the Clinical Products Division at Siemens Healthcare, will join Clariant on April 1, 2016.
“We are very pleased that Britta Fuenfstueck will join Clariant. With her extensive international experience as a senior executive in the technology industry, she will be a strong addition to our management team and will bring valuable insights and perspectives,” said Hariolf Kottmann, CEO. “I look forward to Britta Fuenfstueck’s contributions toward the long-term development of Clariant and her support for our top priority: to generate value for our customers, our employees, our company, and our shareholders.”
Britta Fuenfstueck (43) has been CEO of the Clinical Products Division at Siemens Healthcare since 2013. During her career with Siemens, she held various leadership positions, including CEO of the Molecular Imaging Business Unit, Vice President, Strategy and M&A for the Healthcare Sector, as well as Director, Product Portfolio and Planning, Marketing and Sales, for Siemens’ Magnetic Resonance Business Unit. Britta Fuenfstueck studied engineering physics at the Johannes Kepler University in Linz, Austria. She began her career with the Boston Consulting Group in 1998.
As of April 1, 2016, the Executive Committee of Clariant will consist of CEO Hariolf Kottmann, CFO Patrick Jany, Britta Fuenfstueck, and Christian Kohlpaintner.
Reader enquiries
Clariant International Ltd
Rothausstrasse 61
4132 Muttenz 1
Switzerland
Notes for editors
Clariant is a globally leading specialty chemicals company, based in Muttenz near Basel/Switzerland. On December 31, 2014 the company employed a total workforce of 17 003. In the financial year 2014, Clariant recorded sales of CHF 6.116 billion for its continuing businesses. The company reports in four business areas: Care Chemicals, Catalysis, Natural Resources, and Plastics & Coatings. Clariant’s corporate strategy is based on five pillars: increase profitability, reposition portfolio, add value with sustainability, foster innovation and R&D, and intensify growth.
Editorial enquiries
Carsten Seum
Clariant International Ltd
Claudia Kamensky
Clariant International Ltd
claudia.kamensky@clariant.com
Anja Pomrehn
Investor Relations
Clariant International Ltd
Siegfried Schwirzer
Investor Relations
Clariant International Ltd
Also available in